UK Patient Support Programs (PSP) Market Analysis

UK Patient Support Programs (PSP) Market Executive Analysis

The UK Patient Support Programs (PSP) market size is at around $xx Bn in 2022 and is projected to reach $xx Bn in 2030, exhibiting a CAGR of 7.9% during the forecast period. The Department for Health and Social Care's budget provides funding for health services in England. In England, the Department of Health and Social Care anticipates spending $192.78 Bn in 2022–23 on these programs. National Health Service (NHS) England and NHS Improvement receive the majority of the Department's funds for use in paying for healthcare services. Compared to earlier forecasts, NHS England will receive a cash rise of $3.53 Bn in 2023–24 and 2024–25. Over the next two years, spending on NHS England will increase by 2% on average in real terms. Over the next two years, the whole Department of Health and Social Care budget will increase by 1.2% in real terms on average, which is significantly less than the historical average.

Patient Support Programs (PSPs) are maintained by several pharmaceutical companies to aid patients and/or medical professionals in better-managing disease and maximizing treatment. PSPs include a range of patient-directed interventions, from specific programs that attempt to educate patients and monitor patients on a particular medication to programs that specifically aim to improve illness management regardless of the patient's treatment. PSPs are now only recognized by organized systems in which a Marketing Authorization Holder (MAH) receives and gathers data regarding the use of its pharmaceuticals, according to a more limited definition of PSPs published by the European Medicines Agency (EMA). Alcura provides individualized medication adherence programs in the UK that can assist patients in getting the best results for their health. These programs include patient education and counseling provided by call centers or nurses.

Market Dynamics

Market Growth Drivers

In the UK, PSP use in healthcare is increasing along with other technological advancements. Patients can now get help and resources from the comfort of their homes because of digital technologies like smartphone apps and telehealth platforms. In order to differentiate their medications and enhance patient outcomes, pharmaceutical companies in the UK are investing more and more in inpatient assistance initiatives thereby resulting in the expansion of the UK PSP market.

Market Restraints

Despite the growing popularity of PSPs in the UK, there is still a lack of understanding about the benefits of these programs among patients and healthcare providers. Due to this, enrolling patients in the programs may be challenging, and healthcare practitioners may be less likely to implement PSPs.

Major Patient Support Programs in the UK​

Top PSP Operators in the UK

1. Wren Healthcare- Wren Healthcare is a global provider of home healthcare services providing highly trained, qualified, and experienced nursing services to the biopharmaceutical and medical device industry
2. Alcura- Alcura partners with healthcare companies, professionals, and organizations to provide innovative personalized solutions that improve patient care and treatment experience and has a presence in various European countries
3. Atlantis Health- Atlantis Health is on a mission to improve people’s experience of healthcare through the design and delivery of personalized behavior change programs that empower people to engage with a wide range of health conditions in a more meaningful way
4. Marti Farm- Marti Farm is a pharma consultancy company, that helps develop products and comply with safety procedures with their intricate workflows
5. Ashfield Engage- Ashfield Engage is a leading provider of field nursing, contact center, and omnichannel patient care services to the healthcare industry that provides state-of-the-art patient engagement programs

Healthcare Policies and Regulatory Landscape

In the UK, the Association of the British Pharmaceutical Industry (ABPI) issued "Guidance Notes for patient safety and Pharmacovigilance in patient support programs" in 2011. The UK has industry codes specifically addressing PSPs and, in some cases, patient safety and data requirements or interactions with healthcare professionals (HCPs) and patients in connection with PSPs

Under ABPI guidance, PSPs typically include:

• Compliance/adherence programs where consenting patients on medication are contacted to see how they are managing their medication
• Call centers where patients or patient carers can contact the marketing authorization holder (MAH) to obtain further information on medication or a particular disease area as part of a structured program
• Nurse-educator programs where nurses (either employed directly by a MAH or through a third party) interact directly with patients to provide education or disease awareness, to help them properly administer medications and manage their disease
• Homecare (home delivery, homecare programs, or homecare services), is a homecare medicine delivery service that can be described as a service that delivers ongoing medicine supplies and, where necessary, associated care, initiated by the hospital prescriber, direct to the patient’s home with their consent with the purpose to improve patient care and choice of their clinical treatment